GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapid Dose Therapeutics Corp (OTCPK:RDTCF) » Definitions » Price-to-Owner-Earnings

RDTCF (Rapid Dose Therapeutics) Price-to-Owner-Earnings : (As of Apr. 14, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Rapid Dose Therapeutics Price-to-Owner-Earnings?

As of today (2025-04-14), Rapid Dose Therapeutics's share price is $0.1393. Rapid Dose Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Rapid Dose Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


RDTCF's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.09
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-04-14), Rapid Dose Therapeutics's share price is $0.1393. Rapid Dose Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Nov. 2024 was $-0.03. Therefore, Rapid Dose Therapeutics's PE Ratio (TTM) for today is At Loss.

As of today (2025-04-14), Rapid Dose Therapeutics's share price is $0.1393. Rapid Dose Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.03. Therefore, Rapid Dose Therapeutics's PE Ratio without NRI for today is At Loss.


Rapid Dose Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Rapid Dose Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapid Dose Therapeutics Price-to-Owner-Earnings Chart

Rapid Dose Therapeutics Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Rapid Dose Therapeutics Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Rapid Dose Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Rapid Dose Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rapid Dose Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rapid Dose Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Rapid Dose Therapeutics's Price-to-Owner-Earnings falls into.


;
;

Rapid Dose Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Rapid Dose Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.1393/-0.03
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rapid Dose Therapeutics  (OTCPK:RDTCF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Rapid Dose Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Rapid Dose Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Rapid Dose Therapeutics Business Description

Traded in Other Exchanges
Address
1121 Walkers Line, Unit 3, Burlington, ON, CAN, L7N 2G4
Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.

Rapid Dose Therapeutics Headlines